Developer docs
API playgroundTry for free, no card

Search company profiles

RadTran

Full company profile

uuid002p4k7

Namestring
RadTran
Legal namestring
RadTran LLC
Websiteurl
radtran.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

RadTran is a nuclear technology company founded in 2012 in Centennial, Colorado by Saleem Drera, PhD, focused on developing methods to produce medical radioisotopes used in targeted alpha therapies (TAT) for cancer treatment. The company's core innovation is its patent-protected IsoCap-AA technology, which enables single-step extraction of medically valuable isotopes—including Ra-224, Ra-226, Ra-228, Ac-225, Pb-212, and Bi-213—from naturally occurring Thorium-232 and Uranium-238, both of which are abundant waste byproducts of mining. By avoiding reactor-based production and multi-step chemical separations, the technology is positioned to address the documented global shortage of alpha-emitting isotopes that is delaying clinical trials and constraining commercialization of TAT drugs.

The company's product portfolio covers four production pathways: Ra-224 from Th-232 (for Pb-212/Bi-212 therapies), Ra-226 from U-238 (precursor for Ac-225 and Ra-223), Ac-225/Bi-213 from Th-232 via Ra-228 neutron targets, and Ac-225/Ra-225 from U-233 or Th-229. As of the data, RadTran operated with 1–10 employees, was not generating commercial revenue, and was funded primarily through non-dilutive government grants including a 2020 DOE STTR Phase I award and a 2021 NCI SBIR Phase I grant, supplemented by a French government export license for thorium exchange with Solvay in 2019.

RadTran's intended business model combines direct medical isotope sales to pharmaceutical companies with technology licensing revenue in the form of a 2% royalty on future radium sales. In August 2024, Energy Fuels Inc. (NYSE: UUUU; TSX: EFR) acquired RadTran for $1.5M cash, $1.5M in common shares, a 2% royalty, and up to $14M in performance-based milestones, with the founder Saleem Drera joining Energy Fuels as VP of Radioisotopes, Radiological Systems, and Intellectual Property. Post-acquisition, RadTran's technology is integrated into Energy Fuels' White Mesa Mill in Utah—the only conventional uranium mill operating in the United States—with commercial-scale production of Ra-226 and potentially Ra-228 targeted for 2026–2028, contingent on engineering completion, offtake agreements, and regulatory approvals.

Short descriptiontext

RadTran is a nuclear technology company that developed the patent-protected IsoCap-AA process for extracting medical radioisotopes (Ra-224, Ra-226, Ac-225, Pb-212, Bi-213) from thorium and uranium mining byproducts to supply pharmaceutical companies developing targeted alpha therapies for cancer. Acquired by Energy Fuels in August 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCentennial, United States
HQ citystring
Centennial
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical isotope production, radioisotope separation, targeted alpha therapy, nuclear medicine supply, thorium processing technology
Industry3 codes
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Miscellaneous Chemical Products2890
Product category
Medical Isotope Production
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Isotope Sales
TypeHardware Sales
Description

Sale of produced radium isotopes (Ra-226, Ra-228) and derived medical isotopes (Ac-225, Pb-212, Bi-213) to pharmaceutical companies for use in targeted alpha therapies for cancer treatment. Revenue contingent on successful R&D, pilot production, and commercial-scale production at Energy Fuels' White Mesa Mill.

radtran.com
2Technology Licensing and Royalties
TypeLicensing Royalties
Description

Revenue from licensing proprietary isotope separation technology. The acquisition by Energy Fuels includes a 2% royalty on future revenues from the sale of produced radium. The company also holds patents for processing and separation of radioactive isotopes.

radtran.com
3Government Grants and R&D Contracts
TypeProfessional Services
Description

Revenue from SBIR Phase I grants (NIH/NCI) and STTR awards (DOE) supporting commercialization of isotope production processes. National Cancer Institute grant awarded September 2021; DOE STTR Phase I award received January 2020.

radtran.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RadTran develops and licenses patent-protected IsoCap-AA technology for the efficient extraction of medical radioisotopes (Ra-224, Ac-225, Ra-226, Ra-228, Pb-212, Bi-213) from naturally occurring stockpiles of Thorium-232 and Uranium-238. The company supplies these isotopes to pharmaceutical companies developing targeted alpha therapy (TAT) cancer drugs, addressing the critical global shortage of alpha-emitter isotopes needed for emerging cancer therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Dramatically lower cost production of medical isotopes compared to existing expensive methods
+1 more record
Product overview1 text field

RadTran is a technology development company offering a portfolio of radioisotope separation technologies centered on its core IsoCap-AA patent-protected technology. The company provides specialized production services for medical radioisotopes used in Targeted Alpha Therapies (TAT) for cancer treatment, including Ra-224 from Th-232, Ra-226 from U-238, Ac-225/Bi-213 from Th-232, and Ac-225/Ra-225 from U-233 or Th-229. These offerings are designed to address the global shortage of alpha-emitter isotopes (Pb-212, Ac-225, Bi-213, Ra-224, Ra-223) critical for emerging cancer therapeutics.

Product and service5 records
1IsoCap-AA Technology
CategoryIsotope Separation Technology
Description

Patent-protected isotope separation technology enabling efficient extraction of Ra-224 and Ac-225 from naturally occurring stockpiles of Thorium-232 (a natural waste byproduct of mining). The technology is licensed and sold to pharmaceutical and nuclear industry partners as a standalone offering.

2Ra-224 Production from Th-232
CategoryMedical Isotope Production Service
Description

Concentration of Ra-224 isotope for emerging Pb-212/Bi-212 cancer therapies. Ra-224 is source material loaded onto generators for hospital delivery of Pb-212 to patients, with potential for direct administration via microspheres. Available to pharmaceutical companies and healthcare providers.

3Ra-226 Production from U-238
CategoryMedical Isotope Production Service
Description

Concentration of Ra-226 from natural or depleted uranium for production of Ac-227 via neutron activation (parent of Ra-223) or Ac-225 via particle accelerator (p,2n) reaction. Sold to pharmaceutical companies and research institutions for use in cancer therapy and research.

4Ac-225/Bi-213 Production from Th-232
CategoryMedical Isotope Production Service
Description

Concentration of Ra-228 from natural thorium for fabrication of neutron irradiation targets to produce Th-229, parent of medically attractive Ac-225 and Bi-213. Requires single neutron capture versus triple neutron capture for competing methods. Targeted at pharmaceutical companies developing TAT cancer drugs.

5Ac-225 and Ra-225 Production from U-233 or Th-229
CategoryMedical Isotope Production Service
Description

Separation technology for extracting Ra-225 and Ac-225 from U-233 or Th-229 sources, simplifying Ac-225 acquisition with fewer steps, simplified extraction, and automation potential. Designed for pharmaceutical and nuclear industry customers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-16
Description

Energy Fuels acquired RadTran LLC in August 2024 for $1.5M cash + $1.5M in common shares + 2% royalty on future radium revenues, plus up to $14M in performance-based milestones. The acquisition combines Energy Fuels' White Mesa Mill processing capabilities and 40+ years of chemical separations experience with RadTran's IP and medical isotope expertise. RadTran's technology will be integrated into Energy Fuels' operations for commercial-scale production of medical isotopes for TAT cancer treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-29
Description

Strategic Alliance Agreement established in July 2021 to evaluate feasibility of recovering Ra-226 and Ra-228 from existing uranium process streams at Energy Fuels' White Mesa Mill in Utah. This partnership preceded the 2024 acquisition and demonstrated successful collaboration on radioisotope recovery evaluation.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2019-07-01
Description

Export License and End User Agreement with French government to exchange thorium held by Solvay. First shipment of thorium expected in early 2020 to support proof of concept and scalability testing for RadTran process. Experimental work conducted at Pacific Northwest National Laboratory.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

All experimental work for DOE STTR award project being conducted at PNNL. Includes Ra-228 product proof of concept demonstration, Ra-228 to Th-229 conversion demonstration, and process scalability testing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest nuclear medicine manufacturer producing SPECT, PET, and therapeutic radioisotopes globally. Comparable as a broad incumbent in medical isotope manufacturing with overlapping pharmaceutical customers.

TypeBroad incumbent
Description

Commercial-stage radiopharmaceutical company with approved and pipeline diagnostic and therapeutic products. Comparable as a TAT-adjacent radiopharmaceutical developer and a likely offtake customer for medical isotopes.

TypeEmerging player
Description

Clinical-stage radiopharmaceutical company developing Pb-212-based targeted alpha therapies with proprietary isotope production capabilities. Comparable as an emerging Pb-212 producer and TAT developer.

TypeEmerging player
Description

Belgian joint venture between IBA and SCK CEN focused on large-scale production of actinium-225 (Ac-225) for targeted alpha therapy. Directly comparable as an emerging alpha-emitter producer addressing the same Ac-225 supply bottleneck RadTran targets.

TypeDirect peer
Description

US-based medical isotope producer (Mo-99/Tc-99m) actively expanding into actinium-225 production. Comparable as a domestic US medical isotope manufacturer with overlapping pharmaceutical customer base and competing for the same supply gap.

TypeBroad incumbent
Description

Established radiopharmaceutical company with diagnostic imaging agents and growing therapeutic pipeline. Comparable as a radiopharmaceutical customer/competitor and a likely end-user of medical isotopes RadTran produces.

TypeBroad incumbent
Description

Operates the largest radiopharmaceutical distribution network in the US. Comparable as a downstream radiopharmacy/distributor in the medical isotope value chain RadTran supplies.

TypeBroad incumbent
Description

Through its Algeta acquisition, Bayer markets Xofigo (Ra-223 dichloride), the first commercially approved alpha-emitting radiopharmaceutical. Comparable as a major incumbent in radium-based TAT with established isotope supply chain.

TypeDirect peer
Description

Munich-based radiopharmaceutical company producing medical radioisotopes including Lu-177 and emerging alpha-emitters for cancer therapy. Comparable as a vertically integrated medical isotope supplier serving pharmaceutical TAT programs.

TypeDirect peer
Description

Subsidiary of Orano specializing in lead-212 (Pb-212) based targeted alpha therapy, using thorium-228/Ra-224 generator systems. Directly comparable as a Pb-212/Ac-225 therapeutic isotope producer with similar end-customers in TAT.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RadTran

Medical Isotope Productionradtran.com

RadTran is a nuclear technology company that developed the patent-protected IsoCap-AA process for extracting medical radioisotopes (Ra-224, Ra-226, Ac-225, Pb-212, Bi-213) from thorium and uranium mining byproducts to supply pharmaceutical companies developing targeted alpha therapies for cancer. Acquired by Energy Fuels in August 2024.

What RadTran does

RadTran is a nuclear technology company founded in 2012 in Centennial, Colorado by Saleem Drera, PhD, focused on developing methods to produce medical radioisotopes used in targeted alpha therapies (TAT) for cancer treatment. The company's core innovation is its patent-protected IsoCap-AA technology, which enables single-step extraction of medically valuable isotopes—including Ra-224, Ra-226, Ra-228, Ac-225, Pb-212, and Bi-213—from naturally occurring Thorium-232 and Uranium-238, both of which are abundant waste byproducts of mining. By avoiding reactor-based production and multi-step chemical separations, the technology is positioned to address the documented global shortage of alpha-emitting isotopes that is delaying clinical trials and constraining commercialization of TAT drugs.

The company's product portfolio covers four production pathways: Ra-224 from Th-232 (for Pb-212/Bi-212 therapies), Ra-226 from U-238 (precursor for Ac-225 and Ra-223), Ac-225/Bi-213 from Th-232 via Ra-228 neutron targets, and Ac-225/Ra-225 from U-233 or Th-229. As of the data, RadTran operated with 1–10 employees, was not generating commercial revenue, and was funded primarily through non-dilutive government grants including a 2020 DOE STTR Phase I award and a 2021 NCI SBIR Phase I grant, supplemented by a French government export license for thorium exchange with Solvay in 2019.

RadTran's intended business model combines direct medical isotope sales to pharmaceutical companies with technology licensing revenue in the form of a 2% royalty on future radium sales. In August 2024, Energy Fuels Inc. (NYSE: UUUU; TSX: EFR) acquired RadTran for $1.5M cash, $1.5M in common shares, a 2% royalty, and up to $14M in performance-based milestones, with the founder Saleem Drera joining Energy Fuels as VP of Radioisotopes, Radiological Systems, and Intellectual Property. Post-acquisition, RadTran's technology is integrated into Energy Fuels' White Mesa Mill in Utah—the only conventional uranium mill operating in the United States—with commercial-scale production of Ra-226 and potentially Ra-228 targeted for 2026–2028, contingent on engineering completion, offtake agreements, and regulatory approvals.

RadTran firmographics

Firmographics
Name
RadTran
Legal name
RadTran LLC
Website
https://radtran.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
1–10 employees
Short description
RadTran is a nuclear technology company that developed the patent-protected IsoCap-AA process for extracting medical radioisotopes (Ra-224, Ra-226, Ac-225, Pb-212, Bi-213) from thorium and uranium mining byproducts to supply pharmaceutical companies developing targeted alpha therapies for cancer. Acquired by Energy Fuels in August 2024.
Ownership category
akta.pro rank

RadTran industry classification

Industry
Product category
Medical Isotope Production
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Medical isotope production
  • Radioisotope separation
  • Targeted alpha therapy
  • Nuclear medicine supply
  • Thorium processing technology

Where RadTran is headquartered

Location

Headquarters

HQ city
Centennial
HQ country
United States
HQ region
North America

Markets served

RadTran business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Isotope Sales: Sale of produced radium isotopes (Ra-226, Ra-228) and derived medical isotopes (Ac-225, Pb-212, Bi-213) to pharmaceutical companies for use in targeted alpha therapies for cancer treatment. Revenue contingent on successful R&D, pilot production, and commercial-scale production at Energy Fuels' White Mesa Mill.
  2. Technology Licensing and Royalties: Revenue from licensing proprietary isotope separation technology. The acquisition by Energy Fuels includes a 2% royalty on future revenues from the sale of produced radium. The company also holds patents for processing and separation of radioactive isotopes.
  3. Government Grants and R&D Contracts: Revenue from SBIR Phase I grants (NIH/NCI) and STTR awards (DOE) supporting commercialization of isotope production processes. National Cancer Institute grant awarded September 2021; DOE STTR Phase I award received January 2020.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

RadTran product offering

Product offering

Core offering

RadTran develops and licenses patent-protected IsoCap-AA technology for the efficient extraction of medical radioisotopes (Ra-224, Ac-225, Ra-226, Ra-228, Pb-212, Bi-213) from naturally occurring stockpiles of Thorium-232 and Uranium-238. The company supplies these isotopes to pharmaceutical companies developing targeted alpha therapy (TAT) cancer drugs, addressing the critical global shortage of alpha-emitter isotopes needed for emerging cancer therapeutics.

Product overview

RadTran is a technology development company offering a portfolio of radioisotope separation technologies centered on its core IsoCap-AA patent-protected technology. The company provides specialized production services for medical radioisotopes used in Targeted Alpha Therapies (TAT) for cancer treatment, including Ra-224 from Th-232, Ra-226 from U-238, Ac-225/Bi-213 from Th-232, and Ac-225/Ra-225 from U-233 or Th-229. These offerings are designed to address the global shortage of alpha-emitter isotopes (Pb-212, Ac-225, Bi-213, Ra-224, Ra-223) critical for emerging cancer therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • IsoCap-AA Technology Patent-protected isotope separation technology enabling efficient extraction of Ra-224 and Ac-225 from naturally occurring stockpiles of Thorium-232 (a natural waste byproduct of mining). The technology is licensed and sold to pharmaceutical and nuclear industry partners as a standalone offering.
  • Ra-224 Production from Th-232 Concentration of Ra-224 isotope for emerging Pb-212/Bi-212 cancer therapies. Ra-224 is source material loaded onto generators for hospital delivery of Pb-212 to patients, with potential for direct administration via microspheres. Available to pharmaceutical companies and healthcare providers.
  • Ra-226 Production from U-238 Concentration of Ra-226 from natural or depleted uranium for production of Ac-227 via neutron activation (parent of Ra-223) or Ac-225 via particle accelerator (p,2n) reaction. Sold to pharmaceutical companies and research institutions for use in cancer therapy and research.
  • Ac-225/Bi-213 Production from Th-232 Concentration of Ra-228 from natural thorium for fabrication of neutron irradiation targets to produce Th-229, parent of medically attractive Ac-225 and Bi-213. Requires single neutron capture versus triple neutron capture for competing methods. Targeted at pharmaceutical companies developing TAT cancer drugs.
  • Ac-225 and Ra-225 Production from U-233 or Th-229 Separation technology for extracting Ra-225 and Ac-225 from U-233 or Th-229 sources, simplifying Ac-225 acquisition with fewer steps, simplified extraction, and automation potential. Designed for pharmaceutical and nuclear industry customers.

Quantifiable outcome

  • Dramatically lower cost production of medical isotopes compared to existing expensive methods
  • +1 more outcomes

Companies that use RadTran

Customer profile

Segments2 records

Ideal customer profiles2 records

RadTran technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

RadTran partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Energy Fuels Inc.coreStrategic or Co-development Partner · 16 August 2024Energy Fuels acquired RadTran LLC in August 2024 for $1.5M cash + $1.5M in common shares + 2% royalty on future radium revenues, plus up to $14M in performance-based milestones. The acquisition combines Energy Fuels' White Mesa Mill processing capabilities and 40+ years of chemical separations experience with RadTran's IP and medical isotope expertise. RadTran's technology will be integrated into Energy Fuels' operations for commercial-scale production of medical isotopes for TAT cancer treatments.
  • Energy Fuels Inc.coreStrategic or Co-development Partner · 29 July 2021Strategic Alliance Agreement established in July 2021 to evaluate feasibility of recovering Ra-226 and Ra-228 from existing uranium process streams at Energy Fuels' White Mesa Mill in Utah. This partnership preceded the 2024 acquisition and demonstrated successful collaboration on radioisotope recovery evaluation.
  • SolvaysupportingTechnology or Integration · 1 July 2019Export License and End User Agreement with French government to exchange thorium held by Solvay. First shipment of thorium expected in early 2020 to support proof of concept and scalability testing for RadTran process. Experimental work conducted at Pacific Northwest National Laboratory.
  • Pacific Northwest National Laboratory (PNNL)supportingStrategic or Co-development PartnerAll experimental work for DOE STTR award project being conducted at PNNL. Includes Ra-228 product proof of concept demonstration, Ra-228 to Th-229 conversion demonstration, and process scalability testing.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

RadTran competitors and assessment

Company assessment

Broad incumbents

  • Curium Pharma: World's largest nuclear medicine manufacturer producing SPECT, PET, and therapeutic radioisotopes globally. Comparable as a broad incumbent in medical isotope manufacturing with overlapping pharmaceutical customers.
  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with approved and pipeline diagnostic and therapeutic products. Comparable as a TAT-adjacent radiopharmaceutical developer and a likely offtake customer for medical isotopes.
  • Lantheus Holdings: Established radiopharmaceutical company with diagnostic imaging agents and growing therapeutic pipeline. Comparable as a radiopharmaceutical customer/competitor and a likely end-user of medical isotopes RadTran produces.
  • Cardinal Health (Nuclear Pharmacy Services): Operates the largest radiopharmaceutical distribution network in the US. Comparable as a downstream radiopharmacy/distributor in the medical isotope value chain RadTran supplies.
  • Bayer (formerly Algeta): Through its Algeta acquisition, Bayer markets Xofigo (Ra-223 dichloride), the first commercially approved alpha-emitting radiopharmaceutical. Comparable as a major incumbent in radium-based TAT with established isotope supply chain.

Emerging players

  • ARTBIO: Clinical-stage radiopharmaceutical company developing Pb-212-based targeted alpha therapies with proprietary isotope production capabilities. Comparable as an emerging Pb-212 producer and TAT developer.
  • PanTera: Belgian joint venture between IBA and SCK CEN focused on large-scale production of actinium-225 (Ac-225) for targeted alpha therapy. Directly comparable as an emerging alpha-emitter producer addressing the same Ac-225 supply bottleneck RadTran targets.

Direct peers

  • NorthStar Medical Radioisotopes: US-based medical isotope producer (Mo-99/Tc-99m) actively expanding into actinium-225 production. Comparable as a domestic US medical isotope manufacturer with overlapping pharmaceutical customer base and competing for the same supply gap.
  • ITM Isotope Technologies: Munich-based radiopharmaceutical company producing medical radioisotopes including Lu-177 and emerging alpha-emitters for cancer therapy. Comparable as a vertically integrated medical isotope supplier serving pharmaceutical TAT programs.
  • Orano Med: Subsidiary of Orano specializing in lead-212 (Pb-212) based targeted alpha therapy, using thorium-228/Ra-224 generator systems. Directly comparable as a Pb-212/Ac-225 therapeutic isotope producer with similar end-customers in TAT.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

RadTran financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RadTran leadership team

Management profile

Number of profiles

Profiles2 records

RadTran funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RadTran M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RadTran

What does RadTran do?

RadTran develops and licenses patent-protected IsoCap-AA technology for the efficient extraction of medical radioisotopes (Ra-224, Ac-225, Ra-226, Ra-228, Pb-212, Bi-213) from naturally occurring stockpiles of Thorium-232 and Uranium-238. The company supplies these isotopes to pharmaceutical companies developing targeted alpha therapy (TAT) cancer drugs, addressing the critical global shortage of alpha-emitter isotopes needed for emerging cancer therapeutics.

Is RadTran a public or private company?

RadTran is a private company. It is classified as corporate owned and is currently acquired.

When was RadTran founded?

RadTran was founded in 2012. It employs 1 to 10 people.

Where is RadTran based?

RadTran is headquartered in Centennial, United States, in the North America region.

How does RadTran make money?

Three revenue lines are on record. Medical Isotope Sales are the primary driver. The others are technology Licensing and Royalties and government Grants and R&D Contracts.

Who are RadTran's main competitors?

Broad incumbents on record are Curium Pharma, Telix Pharmaceuticals, Lantheus Holdings, Cardinal Health (Nuclear Pharmacy Services) and Bayer (formerly Algeta). Emerging players are ARTBIO and PanTera. Direct peers are NorthStar Medical Radioisotopes, ITM Isotope Technologies and Orano Med.

Does RadTran have an API?

No public API is recorded for RadTran.

What industry is RadTran in?

RadTran's product category is Medical Isotope Production. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 3254 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEnergy Fuels Acquires RadTran LLC as A Further Step Toward Addressing the Global Industry Need For Medical Radioisotopes in Emerging Cancer TreatmentsEnergy Fuels acquired RadTran LLC on August 16, 2024, to enhance its medical isotope production capabilities. The deal includes $1.5 million in cash and shares, plus a 2% royalty on future radium revenues, with up to $14 million in performance-based milestones. Energy Fuels plans to produce R&D quantities of Ra-226 by end of 2024 and commercial production by 2026-2028.Investing.comEnergy Fuels Acquires RadTran LLC as A Further Step Toward Addressing the Global Industry Need For Medical Radioisotopes in Emerging Cancer Treatments By Investing.comEnergy Fuels acquired RadTran LLC on August 16, 2024, to enhance its medical isotope production capabilities. The deal includes $1.5 million in cash and shares, plus a 2% royalty on radium revenues, with up to $14 million in performance-based milestones. Energy Fuels plans to produce R&D quantities of Ra-226 by end of 2024 and commercial production by 2026-2028.PR NewswireEnergy Fuels Announces Q2-2021 Results, Including Robust Balance Sheet, Market Leading U.S. Uranium and Vanadium Position & Launch of U.S. Commercial Rare Earth Production; Webcast on August 3, 2021Energy Fuels Inc. reported a net loss of $10.8 million for the second quarter of 2021 while announcing the launch of commercial-scale rare earth carbonate production and deliveries to Neo Performance Materials in Europe. The company also finalized agreements to sell non-core uranium assets to International Consolidated Uranium Inc. for approximately $24 million and established a strategic alliance with RadTran, LLC to explore recovering medical isotopes from its process streams.PR NewswireEnergy Fuels Announces Strategic Alliance with RadTran, LLC for the Recovery of Isotopes Needed for Emerging Cancer TherapeuticsEnergy Fuels Inc. has entered into a Strategic Alliance Agreement with RadTran, LLC to evaluate the recovery of thorium and radium from Energy Fuels' existing rare earth carbonate and uranium process streams at the White Mesa Mill in Utah for use in targeted alpha therapy cancer therapeutics. The initiative aims to address a critical supply bottleneck, as existing domestic and global supplies of these medical isotopes are in short supply and current production methods are costly and unable to scale to meet demand. If the technical and economic feasibility is established and required regulatory approvals are obtained, the alliance could generate significant future revenue for Energy Fuels while supporting the development of a new U.S.-based medical supply chain for cancer therapies.